Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity
Objective Methanogens colonizing the human gut produce methane and influence host metabolism. This study examined metabolic parameters in methane‐producing subjects before and after antibiotic treatment. Methods Eleven prediabetic methane‐positive subjects (9F, 2M) with obesity (BMI 35.17 ± 7.71 kg/...
Saved in:
Published in | Obesity (Silver Spring, Md.) Vol. 24; no. 3; pp. 576 - 582 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.03.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective
Methanogens colonizing the human gut produce methane and influence host metabolism. This study examined metabolic parameters in methane‐producing subjects before and after antibiotic treatment.
Methods
Eleven prediabetic methane‐positive subjects (9F, 2M) with obesity (BMI 35.17 ± 7.71 kg/m2) aged 47 ± 9 years were recruited. Subjects underwent breath testing, symptom questionnaire, oral glucose tolerance test (OGTT), lipid profile, and stool Methanobrevibacter smithii levels, gastric transit, and energy utilization analyses. After a 10‐day antibiotic therapy (neomycin 500 mg bid/rifaximin 550 mg tid), all testing was repeated.
Results
Baseline stool M. smithii levels correlated with breath methane (R = 0.7, P = 0.05). Eight subjects (73%) eradicated breath methane and showed reduced stool M. smithii (P = 0.16). After therapy, methane‐eradicated subjects showed significant improvements in low‐density lipoprotein (LDL) (P = 0.028), total cholesterol (P = 0.01), and insulin levels on OGTT (P = 0.05 at 120 minutes), lower blood glucose levels on OGTT (P = 0.054 at 90 minutes), significant reductions in bloating (P = 0.018) and straining (P = 0.059), and a trend toward lower stool dry weight. No changes were detected in gastric emptying time or energy harvest.
Conclusions
Breath methane eradication and M. smithii reduction are associated with significant improvements in total cholesterol, LDL, and insulin levels and with lower glucose levels in prediabetic subjects with obesity. The underlying mechanisms require further elucidation. |
---|---|
Bibliography: | Cedars‐Sinai has a licensing agreement with Salix Pharmaceuticals. Dr. Mark Pimentel is a consultant for Salix Pharmaceuticals and is on the advisory board for Salix Pharmaceuticals. The other authors declared no conflict of interest. R.M.: designed the study, performed clinical studies, analyzed the data, and wrote the manuscript; K.S.C.: recruited subjects, assisted with clinical studies, and compiled data; W.M.: performed laboratory tests and did the initial data analysis; M.M.: calculated the metabolic rates, designed the diets, monitored subject compliance, and contributed to the manuscript; R.T. and Z.M.: performed additional laboratory testing; D.S. and R.N.B.: performed additional data analysis and contributed to and edited the manuscript; G.M.B.: assisted with troubleshooting experiments and wrote and reviewed the manuscript; S.W.: supervised the laboratory testing; M.P.: analyzed the data and wrote and edited the manuscript. Disclosure Funding agencies This study was supported by an Innovation Award from the American Diabetes Association to Dr. Ruchi Mathur (1‐12‐IN‐28). The Cedars‐Sinai CTRC is supported by the National Center for Research Resources, grant UL1RR033176, and is now at the National Center for Advancing Translational Sciences, grant UL1TR000124. Author contributions SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1930-7381 1930-739X |
DOI: | 10.1002/oby.21385 |